As the CEO and cofounder of Atropos Health, Dr. Brigham Hyde is focused on closing the “evidence gap” that frequently arises in modern medicine. While healthcare decisions often boil down to detective work, the pursuit of the best data to guide decisions is sometimes hamstrung by limited or partial guidance from clinical trials or established…
With Deep Research, the CEO of OMNY Health says we’re still ‘in the first inning’ of AI-assisted research
It may not be perfect, but OpenAI’s Deep Research tool can significantly accelerate mundane internet-based research tasks. You give it an assignment, it asks a few follow-up questions, which you reply and there it goes, thinking and researching your query for about five minutes — or as long as half an hour. Built on OpenAI’s…
Flatiron Health sees shift from “what if” to “what is” in real-world evidence in oncology
“The era of ‘what if’ for AI in healthcare is over. Now, it’s all about ‘what is.’ ” So says Blythe Adamson, head of outcomes research and evidence generation at the real-world evidence platform Flatiron Health, a company reimagining cancer care infrastructure. “Post-ChatGPT,” she states, “the skepticism has vanished.” The proof? Flatiron is seeing data…
For sparse data classification, VersAI’s Extreme AutoML is more accurate and orders of magnitude faster than Google’s AutoML
A new AI technology known as VersAI, a proprietary AI technology from Verseon, is challenging the dominance of deep learning—especially in areas where data is scarce. In a recent preprint, Verseon researchers and a colleague at the Missouri University of Science and Technology show that VersAI can train predictive models considerably faster than Google AutoML, based…
How conversational AI can detect pharma safety events
Pharmaceutical manufacturers are tasked with monitoring and reporting safety events (adverse events, product quality complaints, special situations, etc.) to protect patient safety. This process – detecting, documenting, evaluating, reporting, and following up – is essential to meeting regulatory standards and ensuring optimal patient outcomes. However, many of these critical events are not being captured today. …
From Graz to global — Innophore’s journey with NVIDIA’s BioNeMo
When a 30-person Austrian startup gets showcased by Jensen Huang, CEO of the trillion-dollar tech giant NVIDIA, schedules tend to fill up fast. That’s precisely the case for Innophore, a biotech company tapping NVIDIA’s computational clout with its Catalophore platform to accelerate AI-driven drug safety screening and binding-site analysis. This year, the company was highlighted…
NVIDIA allies with IQVIA, Mayo Clinic and Illumina on healthcare AI
NVIDIA today announced at JP Morgan partnerships with IQVIA, Illumina, Mayo Clinic and Arc Institute that center on accelerating biomedical AI across genomics, drug development, and clinical diagnostics. The collaborations aim to tap advanced computing across the healthcare sector, with IQVIA deploying AI agents for clinical trials, Illumina integrating genomic analysis tools, Mayo Clinic developing…
QuantHealth bolsters leadership to accelerate enterprise-grade clinical AI
Tel Aviv-based QuantHealth is on a roll. In August 2024, it surpasses the 100th mark in simulated clinical trials with an 85% accuracy rate and reported cost savings upwards of $215 million for one major pharmaceutical partner. In March of the same year, Fast Company recognized QuantHealth as one of the most innovative companies in…
Merck taps Atropos Health to accelerate real-world evidence generation
Building on existing integrations with cloud leaders AWS and Google Cloud and collaborations with Arcadia and TD2, Atropos Health is now partnering with Merck. This new collaboration will tap Atropos Health’s GENEVA OS (Generative Evidence Acceleration Operating System) and related tools with the aim of speeding the generation of real-world evidence. Under the agreement, Merck’s…
From biology-first AI to structured digital twin adoption, 4 shifts coming to biopharma R&D in 2025
In 2023, the composite success rate for clinical development in biopharma hit its highest level since 2018 thanks to the adoption of novel trial designs, predictive biomarkers, and digital methodologies, according to IQVIA. But waning R&D productivity is a significant industry concern. A substantial number of life science executives believe their organizations need to rethink…
Why scientific AI needs clear lines of sight — especially for fields like drug development
Today’s large language models can be as unreliable as they are eloquent. Their tendency to fabricate facts and lose the thread makes them risky tools for scientific research, especially in highly regulated industries like pharmaceuticals and chemistry. They also struggle to provide sources and will fabricate a bogus academic journal without batting an eye. Speaking…
2024: The year AI drug discovery and protein structure prediction took center stage—2025 set to amplify growth
The global AI drug discovery market, valued around $1 to $1.7 billion in 2023, will be worth a multiple of that by the decade’s end. Analysts project the sector could be worth $9 billion or more. 2024 Nobel Prize in Chemistry Recipients: David Baker Demis Hassabis John Jumper Achievement: Computational protein design and structure prediction…
Drug development in 2025: 5 expert predictions cover synthetic data, hybrid trials and more
In 2024, we saw the expanded use of synthetic data and natural language processing transform drug discovery and development. In a batch of predictions published in December of 2023, one expert predicted that synthetic data was set to “take off” in drug research. In 2025, the pendulum could begin swinging back the other way, according…
PathAI launches AI tool for analyzing fibrosis in cancer tissue samples
The digital pathology firm PathAI has released PathExplore Fibrosis, an AI-based tool that analyzes fibrosis and collagen structures from H&E-stained whole-slide tissue images. The software quantifies fibrotic areas and collagen fibers from standard pathology slides, replacing specialized staining techniques and microscopy equipment. The tool processes large datasets of tissue images, designed to work with existing…
IQVIA’s AI vision is to cut pharmacovigilance costs by 50% with superhuman accuracy
Pharmaceutical companies could slash their pharmacovigilance costs by half while significantly improving accuracy through generative AI, according to IQVIA’s Global Practice Lead of Pharmacovigilance Technologies, Uwe Trinks. “The idea is: we can save 50% of the cost and get the quality to above 99%,” Trinks said. “That means when we have human verification, we only…
One scientist’s quest to teach machines to see cancer the way doctors do
The conceptual and technological underpinnings of digital pathology have been around for decades, with the virtual microscope emerging in the 1990s. But mainstream adoption remained elusive. For instance, when the digital histopathology service company HistoWiz launched in 2013, its focus was straightforward: provide faster turnaround times than traditional histology labs. Over the years, the company…
Anima Biotech aims to open the ‘black box’ of disease with large-scale cellular experiments
While many AI companies focus on analyzing existing scientific literature, this approach faces a fundamental challenge: the reliability of the source material itself. “Up to 70% of experiments described in publications cannot be replicated,” notes Yochi Slonim, CEO of Anima Biotech. “You do it once and you publish it. You do it again, it doesn’t…
Roche, Novartis lead 2024’s top 50 pharma in oncology (YTD)
Swiss pharma giants Novartis and Roche consistently rank among the top pharma companies in terms of revenue. In 2024, the two companies are also leading in total international patent volume. Meanwhile, smaller firms like Incyte and Vertex Pharma are punching above their weight in market impact. For instance, Incyte, with a market cap of just…
Unlearn on shaving millions off clinical trial budgets with digital twins
Clinical trials are notoriously expensive, with Phase 3 studies costing upwards of around $55,000 per day and completed trials routinely costing in the tens of millions of dollars. The startup Unlearn aims to chip away at those costs using digital twin technology, a concept pioneered by NASA during the Apollo era to create ‘living models’…
How spatial AI is uncovering the hidden truths of breast cancer
Breast cancer is the most common cancer for women in the nation, with over 300,000 new cases expected to be diagnosed this year. While the narrative for breast cancer early detection centers around mammograms, the gold standard for diagnosis, clinicians have tapped into enhancing radiology and X-ray imaging using artificial intelligence (AI). This AI-enhanced approach…
GenAI is an ‘always available intern’ but for delicate pharma tasks, human guidance is critical
ChatGPT may be one of the quickest adopted tech platforms in recent memory, but the potential of it and other large language models ability transform the world has also been met with occasional provider outages, hallucinations, and memory problems. “There’s a lot of resentment towards the hype,” notes Christopher M. McSpiritt, head of life sciences…
Honeywell and Salesforce expand life sciences partnership
Honeywell and Salesforce have announced an expansion of their strategic alliance to deliver an enhanced software platform tailored for the life sciences industry. This expanded platform integrates Honeywell’s TrackWise Quality suite with Salesforce Life Sciences Cloud, Agentforce, Data Cloud, Analytics, and other solutions, aiming to expedite the delivery of vital medications and healthcare devices to…
Q&A: Oracle launches new cloud service to analyze global oncology treatment trends
Traditionally, only a small fraction of oncology drugs make it from phase 1 to commercialization. And biopharmaceutical companies continue to face significant challenges in understanding how new oncology drug approvals affect treatment patterns and market share. To deal with such hurdles, Oracle has recently launched CancerMPact Treatment Architecture Trends (PDF overview here), a resource that…
Scientists develop new machine-learning model to predict immunogenic neoantigens
Researchers at Cleveland Clinic’s Global Center for Immunotherapy, in collaboration with Bristol Myers Squibb, have published a comprehensive study on how the immune system remodels the tumor microenvironment in response to immune checkpoint therapy. This research represents the most detailed analysis of this process to date. Under the leadership of Timothy Chan, MD, PhD, Chair…
How Fovus enabled a biotech to accelerate high-throughput screening by up to 96x with cloud HPC
Let’s face it: Cloud-based High-Performance Computing (HPC) offers unprecedented computational power. These systems can perform quadrillions of calculations per second. But that computational horsepower comes at a price – not just financially, but in the form of a steep learning curve and a constant battle against configuration headaches, unpredictable costs, and delays. For researchers working…